Mayne Pharma Limited’s proposed acquisition of the North American rights to SuperGen, Inc.'s Nipent® (pentostatin for injection) and SurfaceSafe™ (communicated on 22 June 2006) has now been completed, as announced by both companies.
Mayne Pharma Limited (ASX: MYP) will pay SuperGen, Inc. (Nasdaq: SUPG) a total maximum consideration of US$34 million inclusive of approximately US$14 million at completion.
Remaining payments are contingent on key events and product performance.
Source: Supergen, Inc.
.jpg)
Comment Preview